Published on
July 2, 2012
- 07:10 GMT
GSK and Theravance announce positive results from four pivotal phase III studies for once-daily LAMA/LABA (UMEC/VI) in COPD
Issued: Monday 02 July 2012, London UK and South San Francisco, CA Headline results from the pivotal efficacy studies support intention to commence global filings for UMEC/VI from end of 2012, ahead of schedule GlaxoSmithKline plc (LSE: GSK) and …
Distribution channels:
Companies
